Annalisa D'Andrea is a venture partner at Longwood Fund and Chief Scientific Officer of Longwood-founded Immunitas Therapeutics, where she brings more than 25 years of drug discovery and development experience in a variety of organizational settings from start-up to biotech and in big pharma. She is also an independent board member for Engimmune Therapeutics, a soluble TCR company. Previously, she was Chief Scientific Officer at Kiniksa Pharmaceuticals and Vice President and Global Head of Discovery for Immunology and Inflammation at Roche, where she was responsible for discovering and advancing multiple drug candidates to the clinic. Prior to Roche, Annalisa held roles of increasing responsibility at SRI International, including Executive Director and Section Head of Discovery Biology, where she was responsible for developing strategies to advance drugs through discovery and into development. Prior to that, she led the SRI International Center for Immunology, Inflammation, and Infectious Diseases, developing synergistic core expertise leveraging capabilities in vaccinology, autoimmunity, infectious diseases, and inflammation. Before she joined SRI, she worked at Chiron Vaccines in Siena, Italy, an American multinational biotechnology firm that was later acquired by Novartis and most recently by GSK.

Annalisa was educated in Italy and the United States, has authored ~50 publications and is the co-inventor of several patents. She earned a Bachelor of Sciences degree, summa cum laude, from the University of Siena in Italy and her doctoral degree from the University of Florence while training at the Wistar Institute at the University of Pennsylvania. She completed her postdoctoral studies at the DNAX Research Institute in Palo Alto, California.